Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Maryland: - UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
- Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Mercy Medical Center — Baltimore, Maryland
- Greater Baltimore Medical Center — Baltimore, Maryland
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
- MedStar Good Samaritan Hospital — Baltimore, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- Central Maryland Radiation Oncology in Howard County — Columbia, Maryland
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in Maryland: - Research Site — Frederick, Maryland
- Research Site — Glenn Dale, Maryland
- Research Site — Silver Spring, Maryland
- Research Site — Towson, Maryland
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Maryland: - Holy Cross Hospital ( Site 0069) — Silver Spring, Maryland
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Maryland: - Research Site — Baltimore, Maryland
- Research Site — Silver Spring, Maryland
- Research Site — Silver Spring, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins — Baltimore, Maryland
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Maryland: - Clinical Trial Site — Annapolis, Maryland
- Clinical Trial Site — Catonsville, Maryland
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Maryland: - Local Institution - 1035 — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Maryland: - Greenebaum Comprehensive Cancer Center ( Site 0036) — Baltimore, Maryland
- Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0028) — Baltimore, Maryland
- Holy Cross Hospital ( Site 0073) — Silver Spring, Maryland
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 3 Recruiting Network
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with br…
Sponsor: Proton Collaborative Group
NCT ID: NCT05856773
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Maryland: - The John Hopkins Hospital — Baltimore, Maryland
- Maryland Oncology Hematology- Columbia — Rockville, Maryland
Phase 2 Recruiting NIH
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Industry
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the st…
Sponsor: Processa Pharmaceuticals
NCT ID: NCT06568692
Sites in Maryland: - University of Maryland Medical Center (UMMC) — Baltimore, Maryland
Phase 2 Recruiting Network
The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with ea…
Sponsor: Proton Collaborative Group
NCT ID: NCT01766297
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or with…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT02422641
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will …
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06245889
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Phase 1 Recruiting Industry
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Sponsor: Clasp Therapeutics, Inc.
NCT ID: NCT06778863
Sites in Maryland: - Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 1 Recruiting Industry
This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody …
Sponsor: A&G Pharmaceutical Inc.
NCT ID: NCT05627960
Sites in Maryland: - University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Christiana Care - Union Hospital — Elkton, Maryland
- UM Baltimore Washington Medical Center/Tate Cancer Center — Glen Burnie, Maryland
- UM Saint Joseph Medical Center — Towson, Maryland
Phase 4 Recruiting Industry
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…
Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in Maryland: - Research Site — Frederick, Maryland
- Research Site — Glenn Dale, Maryland
Recruiting Industry
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for par…
Sponsor: PreludeDx
NCT ID: NCT03448926
Sites in Maryland: - MedStar Health Research Institute — Baltimore, Maryland
Recruiting Industry
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhance…
Sponsor: EXoPERT
NCT ID: NCT07186296
Sites in Maryland: - John Hopkins University — Baltimore, Maryland